Compare AU
Compare BAOR vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are BAOR and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
BAOR | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 1 | 65 |
Median incremental investment | $993.50 | $990.50 |
Median investment frequency | Daily | Monthly |
Median total investment | $0 | $2,002.03 |
Average age group | N/A | 26 - 35 |
Key Summary
BAOR | DRUG | |
|---|---|---|
Strategy | BAOR.AX was created on 2023-05-01 by AORIS. The fund's investment portfolio concentrates primarily on total market equity. This class aims to achieve annualised returns in excess of the benchmark after all fees and expenses measured over a market cycle, which we consider to be seven years. Returns are not guaranteed. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Aoris Int Fund (Class B) (Unhedged) Active ETF (100 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Other (77.10 %) Communication Services (33.53 %) Health Care (22.75 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 1.1 % | 0.57 % |
Key Summary
BAOR | DRUG | |
|---|---|---|
Issuer | AORIS | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 1.1 % | 0.57 % |
Price | $2.54 | $7.84 |
Size | N/A | $162.958 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | 1.95 % | 1.89 % |
Market | ASX | ASX |
First listed date | 30/04/2023 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
BAOR | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 1 | 65 |
Median incremental investment | $993.50 | $990.50 |
Median investment frequency | Daily | Monthly |
Median total investment | $0 | $2,002.03 |
Average age group | N/A | 26 - 35 |
Pros and Cons
BAOR | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
BAOR | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |